FGF2 and neoplasm: This tumor suppressive activity is associated with 18 kDa LOX-pp, which inhibited FGF-2 signaling in prostate cancer (PCa) [19], oncogenic bcl-2 activity in breast cancer [20], and nuclear factor-κB (NF-κB) activation in lung and prostate carcinoma [10].